Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Medicamen Organics Ltd. Share Price
Day's Range
Day's Range
Low
₹25.65
High
₹26.75
Price Summary
| Previous Close | ₹25.65 |
|---|---|
| Day's Range | ₹25.65 - ₹26.75 |
| Open | ₹25.65 |
| 52 Week Range | ₹19.10 - ₹38.00 |
| Volume | 16,000 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 4.15 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -2.70 |
| P/E Ratio | 6.27 |
| Book Value(₹) | 0.91 |
| PAT Margin (%) | 10.60 |
| Face Value (₹) | 10.00 |
| ROCE(%) | 16.97 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | N/A | 370.88 |
| Expenses | N/A | N/A |
| PBT | N/A | 43.87 |
| Operating profit | N/A | 0.0 |
| Net profit | N/A | 32.71 |
About Medicamen Organics Ltd.
| Founded | 1995 |
|---|---|
| Managing Director | Bal Kishan Gupta |
| NSE Symbol | MEDIORG |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,56,833.38 | 1,904.00 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 2,45,425.70 | 9,245.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,87,319.76 | 4,924.70 | 3,480.60 - 3,480.60 |
| Apollo Hospitals Enterprise Ltd. | 1,26,300.44 | 8,784.00 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,16,820.50 | 672.25 | 0.00 - 0.00 |
| Zydus Lifesciences Ltd. | 1,13,216.68 | 1,135.00 | 835.50 - 835.50 |
| Cipla Ltd. | 1,12,211.54 | 1,389.00 | 1,165.70 - 1,165.70 |
| Laurus Labs Ltd. | 1,01,154.55 | 1,872.15 | 823.10 - 823.10 |
| Lupin Ltd. | 97,626.26 | 2,135.00 | 1,875.00 - 1,875.00 |
| Mankind Pharma Ltd. | 96,859.07 | 2,345.00 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Akums Drugs and Pharmaceuticals informs about ESG rating
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated July 11, 2023 (updated on January 30, 2026), Akums Drugs and Pharmaceuticals has informed that on September 02, 2026, the Company has received an ESG rating of ‘65’ for the Financial Year 2025-26 from NSE Sustainability Ratings & Analytics (‘NSE Sustainability’), a subsidiary of NSE Indices and a registered ESG Rating Provider. The company has informed that it has not engaged NSE Sustainability for ESG Rating and they have voluntarily assigned the aforesaid ESG Rating on the basis of publicly available information. The link of the ESG rating is https://www.nse-esgrating.com/esg-ratings/552?fiscalYear=2024-2025.
The above information is a part of company’s filings submitted to BSE.
Syschem India informs about AGM
Godavari Drugs informs about press release
Dolphin Medical Services informs about AGM
Tyche Industries informs about press release
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Medicamen Organics Ltd. is ₹25.65 as of 2026-09-02.
The market capitalisation of Medicamen Organics Ltd. is ₹38.17 as of 2026-09-02.
The 1-year return of Medicamen Organics Ltd. is -11.35% as of 2026-09-02.
The P/E ratio of Medicamen Organics Ltd. is 6.27 as of 2026-09-04.
The 52-week high and low of Medicamen Organics Ltd. are ₹38.00 and ₹19.10, respectively, as of 2026-09-02.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
